Endo Pharmaceuticals Highlights Commitment to Sustainability in 2023 Report
- Endo, Inc. has released its annual Corporate Responsibility Report, showcasing the advancements made by Endo International plc in 2023.
- The report highlights achievements and activities undertaken before Endo's acquisition of EIP's assets in April 2024.
- This initiative reflects Endo's commitment to corporate responsibility and transparency in its operations.
Endo Pharmaceuticals has reaffirmed its dedication to sustainable and responsible business practices, as outlined by President and CEO Blaise Coleman. In the company’s 2023 report, Coleman emphasized the importance of transforming insights into life-enhancing therapies while maintaining ethical operations. The report showcases significant progress across four key pillars of corporate responsibility. Among the notable achievements, over 99% of Endo employees reported awareness of how to address ethical concerns and compliance questions. The company also made strides in supplier diversity, increasing the number of LGBTQ-owned suppliers by 200%. Safety remains a priority, with an impressive Overall Recordable Incident Rate of 0.1 per 100 employees, a marked improvement from 0.4 in 2022. Additionally, Endo has focused on employee development, with 16% of team members receiving promotions in 2023, aided by robust leadership training programs. The company’s commitment to community engagement is evident, as more than 800 employees in India volunteered over 2,000 hours at 21 charities, positively impacting the lives of 7,350 individuals. The report includes forward-looking statements regarding Endo’s long-term business strategies and corporate responsibility initiatives. While the company believes these statements are based on reasonable assumptions, it advises stakeholders to consider potential risk factors detailed in its public filings with the U.S. Securities and Exchange Commission.